10-Q: Coya Therapeutics Advances ALS Drug, Secures $23M Funding

Coya Therapeutics reported progress on its lead ALS drug candidate, COYA 302, with FDA IND acceptance and a $4.2 million milestone payment, alongside a post-period $23 million public offering.

Summary

• Coya Therapeutics, a clinical-stage biotechnology company, is focused on developing therapies to enhance Regulatory T cells (Tregs) for neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases.
• The company's lead asset, COYA 302, a dual biologic for ALS, received FDA Investigational New Drug (IND) application acceptance on August 29, 2025, allowing for a Phase 2 clinical study.
• Following IND acceptance, Coya received a $4.2 million milestone payment from Dr. Reddy's under their Development and License Agreement.
• For the three months ended September 30, 2025, the net loss was $2.1 million, an improvement from $4.0 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss increased to $15.5 million from $12.0 million in the prior year period.
• Collaboration revenue for the three months ended September 30, 2025, was $3.6 million, primarily from the immediate recognition of $3.3 million in License revenue due to the IND acceptance.
• Research and development expenses increased to $2.9 million for the quarter and $11.8 million for the nine months ended September 30, 2025, driven by the clinical advancement of COYA 302.
• As of September 30, 2025, cash and cash equivalents stood at $28.1 million, with an accumulated deficit of $56.3 million.
• Post-period, on October 27, 2025, the company closed a public offering, raising approximately $23.0 million in gross proceeds by selling 4,181,818 shares at $5.50 per share.
• The company expects its current cash, combined with the offering proceeds, to fund operations for at least one year from the financial statements' issuance date (November 12, 2025).

Sentiment

Score: 7

Explanation: The company achieved significant clinical and financial milestones, including FDA IND acceptance for its lead ALS candidate and a substantial post-period capital raise, which positively impacts its liquidity and ability to fund operations for the next year. While operating losses continue, the progress in development and funding are strong positive indicators for a clinical-stage biotech.

Positives

• FDA accepted the Investigational New Drug (IND) application for COYA 302 for the treatment of ALS on August 29, 2025, enabling the initiation of a Phase 2 clinical study.
• Received a $4.2 million milestone payment from Dr. Reddy's following the FDA's IND acceptance for COYA 302.
• Reported positive in vitro study results for COYA 303 (LD IL-2 and GLP-1RA), showing a statistically significant 42% increase in Treg suppressive function compared to single agents.
• Issued a U.S. patent on June 2, 2025, for a highly stable liquid formulation of IL-2, enhancing intellectual property for COYA 301.
• Net loss for the three months ended September 30, 2025, decreased to $2.1 million from $4.0 million in the prior year, and net loss per share decreased to $0.13 from $0.26.
• Successfully completed a public offering on October 27, 2025, raising approximately $23.0 million in gross proceeds, significantly bolstering liquidity.

Negatives

• Net loss for the nine months ended September 30, 2025, increased to $15.5 million from $11.9 million in the same period of 2024.
• Cash and cash equivalents decreased to $28.1 million as of September 30, 2025, from $38.3 million at December 31, 2024.
• Accumulated deficit grew to $56.3 million as of September 30, 2025, indicating continued operating losses since inception.
• Net cash used in operating activities increased to $9.7 million for the nine months ended September 30, 2025, compared to $7.9 million in the prior year period, reflecting higher cash burn.
• The company will need substantial additional financing beyond the recent offering to fund its operations and product development, with no assurance of availability on acceptable terms.

Risks

• Ability to develop, obtain regulatory approval for, and commercialize product candidates is uncertain.
• Timing of future investigational new drug (IND) submissions, initiation of preclinical studies and clinical trials, and expected clinical results are subject to variability.
• Success in early preclinical studies may not be indicative of results obtained in later studies or clinical trials.
• Impact of any global health events, including endemics or pandemics, on preclinical studies and any future clinical trials.
• Potential benefits of product candidates may not be realized.
• Ability to identify patients with the diseases treated by product candidates, and to enroll patients in clinical trials.
• Success of efforts to expand the pipeline of product candidates and develop marketable products through therapeutic modalities.
• Expectations regarding collaborations and other agreements with third parties and their potential benefits.
• Ability to obtain, maintain, and protect intellectual property.
• Reliance upon intellectual property licensed from third parties.
• Ability to identify, recruit, and retain key personnel.
• Current and future capital requirements to support development and commercialization efforts for product candidates and ability to satisfy capital needs.
• Ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions, potential future global pandemics or health crises, and disruptions to, and volatility in, the credit and financial markets in the United States.
• Inadequate funding for the FDA, the U.S. Securities and Exchange Commission (SEC), and other U.S. government agencies or the European Medicines Agency (EMA) or comparable foreign regulatory authorities, including from government shutdowns, could prevent product candidates from being developed or commercialized in a timely manner.
• A prolonged government shutdown, significant leadership, personnel, and/or policy changes, or other substantial modification in agency activities could significantly impact the ability of the FDA to timely review and process regulatory submissions, which could have a material adverse effect on the business.
• Future government shutdowns could impact the ability to access the public markets and obtain necessary capital.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances product candidates through clinical trials and seeks regulatory approval. Substantial additional capital will be required to support ongoing operations, potential commercialization, and growth strategies, including scaling manufacturing, establishing sales infrastructure, and expanding intellectual property. The company anticipates increased spending in 2025 due to the advancement of COYA 302 in a Phase 2 ALS study and preparation for an IND for COYA 302 in Frontotemporal Dementia (FTD).

Management Comments

• Our operations have consisted of developing our clinical and preclinical product candidates and we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, ongoing business operations and raising capital.
• We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.
• We believe COYA 302 is the most clinically advanced of what we hope will be a family of combination therapies that all feature our LD IL-2, and given the growing list of indications for which we are developing it, we can now refer to COYA 302 as a Pipeline in a Product.
• We believe that these data show that the combination approach of COYA 303 enhances Treg suppressive function in highly inflammatory microenvironments, while also promoting Treg survival by preventing apoptosis.

Industry Context

Coya Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically targeting neurodegenerative, autoimmune, and metabolic diseases by enhancing Regulatory T cells (Tregs). The recent Nobel Prize in Physiology or Medicine awarded to Dr. Shimon Sakaguchi for the discovery of Tregs highlights the growing scientific recognition and potential of this field. The company's focus on combination biologics, particularly with its lead asset COYA 302 for ALS, positions it within a trend of developing multi-pathway therapies for complex conditions. The successful IND acceptance for COYA 302 and the positive in vitro data for COYA 303 suggest progress in a challenging therapeutic area with high unmet medical need.

Legal Proceedings

• No legal proceedings are currently outstanding.

Related Party Transactions

• The company has a Development and License Agreement with Dr. Reddy's Laboratories Ltd. (DRL) and its affiliate, Dr. Reddy's Laboratories SA, for COYA 302 development and commercialization.
• The company has a License Agreement with ARScience Biotherapeutics, Inc. (ARS) for patents related to IL-2 formulations.
• The company has an Amended and Restated Patent Know How and License Agreement with The Methodist Hospital (Methodist) for intellectual property and know-how.
• The company has a Sponsored Research Agreement with Houston Methodist Research Institute (HMRI), an affiliate of Methodist, to fund research.

Stakeholder Impact

• **Shareholders**: The successful public offering provides capital, reducing immediate dilution risk but future capital raises are still anticipated. Clinical progress with COYA 302 for ALS could increase long-term value, but ongoing losses and the need for further financing pose risks.
• **Employees**: Continued R&D activities and potential commercialization efforts suggest stable to growing employment opportunities, particularly in clinical, operational, and management roles.
• **Customers (future patients)**: Progress in COYA 302 for ALS and COYA 303 research offers potential new therapeutic options for neurodegenerative and other diseases with high unmet medical needs.
• **Suppliers/Partners**: Ongoing and increasing R&D expenses, including payments to CROs, CMOs, and research institutions like HMRI, indicate continued engagement and potential for new contracts.
• **Creditors**: The company's reliance on equity financing and lack of committed debt facilities, coupled with significant accumulated deficit, suggests a higher risk profile, though the recent capital raise improves short-term liquidity.

Next Steps

• Initiate the planned Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ALSTARS Trial).
• Receive an additional $4.2 million payment upon the dosing of the first patient in the first Phase 2 clinical trial for COYA 302 for ALS in the United States.
• Continue ongoing and planned research and development of product candidates.
• Initiate nonclinical studies and clinical trials for any additional product candidates.
• Scale up external manufacturing capacity for clinical trials and potential commercialization.
• Prepare for an IND for the study of COYA 302 in patients with Frontotemporal Dementia (FTD).
• Establish a sales, marketing, and distribution infrastructure if any product candidates receive marketing approval.
• Develop, maintain, expand, protect, and enforce intellectual property portfolio.
• Acquire or in-license other product candidates and technologies.
• Add clinical, operational, financial, and management information systems and personnel.

Key Dates

Recommendation

Coya Therapeutics has demonstrated significant progress with its lead candidate, COYA 302, achieving FDA IND acceptance for a Phase 2 ALS study and securing a substantial milestone payment. The post-period capital raise of $23 million significantly improves the company's liquidity, addressing immediate going concern risks and providing runway for the next year. However, the company continues to incur substantial operating losses and has a large accumulated deficit, indicating that profitability is still several years away and dependent on successful clinical development and commercialization. The stock is speculative, typical for a clinical-stage biotech. While the recent positive developments are encouraging, the long-term risks associated with clinical trials, regulatory approvals, and the need for future financing remain high. A 'hold' recommendation reflects the positive momentum and improved financial runway, balanced against the inherent high risks and long development timelines in the biotech sector.

Keywords

Coya Therapeutics, COYA, Biotechnology, Clinical-stage, Regulatory T cells, Tregs, Neurodegenerative diseases, ALS, Amyotrophic Lateral Sclerosis, COYA 302, COYA 301, IL-2, CTLA4-Ig, FDA IND acceptance, Phase 2 clinical trial, Dr. Reddy's Laboratories, Biologics, Immunomodulatory, Public offering, Capital raise, Financial results, SEC filing, 10-Q